Skip to main content
. 2015 Oct 14;6(34):36870–36883. doi: 10.18632/oncotarget.4874

Figure 2. Forest plots displaying multivariate Cox analysis of demographic variables prognostic to PFS and OS in Chinese patients with mRCC treated with sorafenib.

Figure 2

BMI, body mass index; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; OS, overall survival; PFS, progression free survival.